NAD+ precursor trials
A blood rise can be sustained through a trial. The accompanying useful change deserves an answer.
An 8-week blood result
The title of the NR safety and metabolism trial uses “long-term.” The trial lasted 8 weeks. I understand the title in its experimental setting, but the word stretches differently when the subject becomes aging.
Healthy overweight adults received NR, a precursor used in making NAD+, or placebo. Whole-blood NAD+ rose with the amount of NR studied and the elevation was maintained throughout the study. Adverse-event rates did not differ significantly from placebo. That is a clear biochemical result within a defined observation window.
It leaves a quieter question: what happened to the person beyond the blood measurement? Maintaining a higher concentration during supplementation tells us that the intervention continued to affect that measurement. The trial did not demonstrate added years of life, and its safety comparison covers the period observed.
I respect the biochemical achievement over those weeks. The distinction becomes particularly useful when a short study is quoted next to a very long ambition.
Walking and muscle findings
The 60-day NMN trial in healthy middle-aged adults reported increased blood NAD+, improved walking distance and better quality-of-life scores compared with placebo. Its biological-age measure did not increase. I give the walking finding more everyday significance than the age label: distance covered is a task someone actually performed. An unchanged age estimate over that interval establishes no extension of life.
The 10-week NMN trial in prediabetic, postmenopausal women found better muscle insulin sensitivity, meaning that muscle responded more readily to the signal to take sugar from blood. Body composition and HbA1c, the longer-term blood-sugar marker, did not change. That selectivity is interesting. A muscle measurement can improve while other measurements stay put.
These are findings about oral precursors, NMN and NR. They leave open how much benefit persists after treatment ends and whether an early functional change carries into later illness or disability. I would trade grand claims for either answer, followed properly.
The ongoing chemistry
As cells extract energy from food, NAD+ accepts electrons to become NADH, which can pass those electrons onward. It also gets consumed by enzymes involved in DNA repair, gene regulation and inflammation. The review of NAD+ metabolism during aging explains why the body has to make and recycle it continually.
In mice lacking the NAD+-consuming enzyme CD38, NAD+ levels were protected against their age-related decline and mitochondrial function was better preserved. That genetic experiment makes the consumption side compelling. It provides no instruction for human supplementation.
The heart study using human myocardium and a mouse heart-failure model adds an organ-specific complication: restoring NAD+ supported ketone-making chemistry, and cardiac function improved in the mice. Human heart tissue was studied; living people were not treated in that experiment.
The 2025 review of human precursor trials is less expansive than the reputation surrounding NAD+. It describes limited human efficacy, sparse tissue-specific data and only a limited number of human studies consistently observing an age-related fall. I trust that uneven picture more than a universal deficiency story.
Safety and product differences
NAD+ in a compounded injection, NAD+ taken orally and the NMN or NR used in precursor trials require separate evidence. The current research here gives little controlled support for intravenous NAD+. Compounded NAD+ preparations are not FDA-approved medicines; a precursor trial cannot establish their manufacturing quality or safety.
NAD+ supports cell survival and metabolism, which raises a theoretical concern about supporting an existing cancer as well. The concern is context-dependent, and evidence here does not establish that these products cause cancer in people. The human-evidence review gives reason to resist easy extrapolation from rodents.
The unanswered duration questions concern benefit and exposure together. An encouraging comparison over weeks can justify another study. Decades of safe, useful improvement require evidence that reaches those decades.